Page 18 - Scott Hutton News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Posted January 26th, 2021 for Biodesix   Important New Findings Validate Testing Strategies That Support Decision Making for Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC)   BOULDER, CO, January 26, 2021 –Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be featured at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), scheduled for January 28-31, 2021. Findings from these recent s...

BOULDER — Biodesix Inc. (Nasdaq: BDSX) has agreed to build a companion test for HiberCell Inc. as the latter takes its breast cancer drug candidates through clinical trials. In a statement, the Boulder-based Biodesix said it and New York City-based HiberCell will co-develop the test to determine suitable candidates for HiberCell’s candidate treatments for hibernating or relapsed breast cancer. Financial terms of the deal were not disclosed. The collaboration marks Biodesix’s entry into developing tests for a new part of the body. The company historically has focused on developing tests ...

HiberCell and Biodesix Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization Initial program to focus on development of a companion diagnostic for HiberCell's novel immunotherapy, Imprime PGG, to aid in patient selection across multiple oncology programs News provided by Share this article Share this article NEW YORK and BOULDER, Colo., Jan. 13, 2021 /PRNewswire/ -- HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced an agreement with Biodesix, Inc. (Nasdaq: BDSX) to further the devel...

Press release content from Business Wire. The AP news staff was not involved in its creation. Biodesix Anticipates Strong Preliminary Fourth Quarter 2020 Revenue (unaudited) January 8, 2021 GMT BOULDER, Colo.--(BUSINESS WIRE)--Jan 8, 2021-- Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company expects to report record fourth quarter 2020 preliminary unaudited revenue in a range of $25 million to $27 million. The strength in the fourth quarter 2020 was a result of growth in the company’s COVID-19 testing services, lun...

Posted on 552 Purdue University is partnering with a Colorado company led by a Purdue alum to offer rapid antigen COVID-19 testing for undergraduate, graduate and professional students taking classes on the West Lafayette campus who will be living off campus (not in the residence halls or in Fraternity, Sorority and Cooperative Life housing) during the spring 2021 semester. The Protect Purdue Health Center, as part of its comprehensive pre-arrival testing strategy, will team with Boulder-based Biodesix Inc. (Nasdaq: BDSX) to test m...